XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.1
RELATED PARTY TRANSACTIONS (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 4 Months Ended 6 Months Ended 12 Months Ended 15 Months Ended
Jun. 28, 2019
Jun. 27, 2019
Oct. 09, 2015
Jul. 31, 2017
Mar. 31, 2017
Mar. 31, 2021
Jun. 27, 2019
Dec. 31, 2020
Dec. 31, 2019
Jul. 31, 2021
Related Party Transaction [Line Items]                    
Aggregate principal of promissory notes and accrued interest               $ 6,000    
Number Of Common Stock Need To Hold To Designate As Director       600,000            
Proceeds from License Fees Received     $ 5,000              
Warrant to purchase shares of common stock 10,000,000                  
Class Of Warrants Or Rights, Expiry Period       5 years            
AD Pharma Agreement                    
Related Party Transaction [Line Items]                    
Proceeds from License Fees Received $ 350                  
Subsequent event | AD Pharma Agreement                    
Related Party Transaction [Line Items]                    
Proceeds from License Fees Received                   $ 200
MainPointe (Nexafed)                    
Related Party Transaction [Line Items]                    
Proceeds from License Fees Received         $ 2,500          
Asset Transferred, License Agreement         $ 309          
Licensing Agreement, Royalty Percentage         7.50%          
MainPointe (Nexafed) | Royalty                    
Related Party Transaction [Line Items]                    
Royalty revenues               9 $ 16  
Investor                    
Related Party Transaction [Line Items]                    
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 0.528            
Warrant to purchase shares of common stock       1,782,531            
Investor | Private Placement                    
Related Party Transaction [Line Items]                    
Sale of Stock, Consideration Received on Transaction       $ 4,000            
Sale of Stock, Number of Shares Issued in Transaction       8,912,655            
Sale of Stock, Price Per Share       $ 0.4488            
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 0.528            
Sale Of Stock, Issue Price Description       85%            
Warrants Not Settleable in Cash, Fair Value Disclosure               495    
Proceeds from Issuance of Warrants               $ 4,000    
Warrant to purchase shares of common stock       1,782,532            
Schutte                    
Related Party Transaction [Line Items]                    
Aggregate principal of promissory notes and accrued interest $ 6,000                  
Fixed interest rate 7.50%                  
Share Price $ 0.16                  
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01                  
Debt Conversion, Converted Instrument, Shares Issued 37,500,000                  
Proceeds from Issuance of Long-term Debt $ 725 $ 650         $ 650      
Schutte | AD Pharma Agreement                    
Related Party Transaction [Line Items]                    
Aggregate principal of promissory notes and accrued interest $ 6,000                  
Debt Conversion, Converted Instrument, Warrants or Options Issued 10,000,000                  
Abuse Deterrent Pharma, LLC | AD Pharma Agreement                    
Related Party Transaction [Line Items]                    
Proceeds from License Fees Received $ 350                 200
Abuse Deterrent Pharma, LLC | Subsequent event                    
Related Party Transaction [Line Items]                    
Reimbursable development expense           $ 100        
Abuse Deterrent Pharma, LLC | Subsequent event | AD Pharma Agreement                    
Related Party Transaction [Line Items]                    
Proceeds from License Fees Received                   $ 200
Reimbursable development expense           $ 200        
Abuse Deterrent Pharma, LLC | MainPointe (Nexafed)                    
Related Party Transaction [Line Items]                    
Option product exercise price waived if the exercise of the option occurred by five years $ 500                  
Period to waive option product exercise price 5 years